Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ): The innovative drug BIOS-0625 tablets have received the notice of clinical trial approval.

Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) announced that the company recently learned that its self-developed innovative drug BIOS-0625 tablets has received the clinical trial approval notification from the National Medical Products Administration (NMPA). Ulcerative colitis, as a chronic recurrent inflammatory disease of the gastrointestinal tract, poses a persistent therapeutic challenge due to its "incurable and recurrent" course. Traditional medicines can provide short-term relief of symptoms but are often limited by three major obstacles: low efficacy ceiling, significant adverse reactions, and poor patient tolerance. New molecules and new treatments are not only the cornerstone of improving the quality of life for patients, but also the key bridge connecting translational medicine with long-term benefits for patients. BIOS-0625 tablets, developed independently by the company, is a new drug targeting ulcerative colitis, with no currently available drug on the market for this target. BIOS-0625 tablets are classified as a "innovative drug not yet marketed domestically or internationally," with a registration category of Class 1 chemical drugs.